TECH vs TSHA · P/E 65, rev $1.22B vs rev $8.3M
Bio-Techne Corp (TECH) versus Taysha Gene Therapies Inc (TSHA) — a side-by-side from cached financials, not a winner call.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Taysha Gene Therapies Inc (TSHA) is a biotechnology company listed on US.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Latest reported TSHA revenue for 2024-12-31 was $8.3M. Net income was -$89.3M. Revenue was down 46.1% from 2023-12-31 to 2024-12-31. TSHA currently screens at market cap $640.7M.
TECH currently screens at market cap $8.49B and trailing P/E 65.2. TSHA currently screens at market cap $640.7M.
Not investment advice. Open the TECH and TSHA stock pages for the full models.
Not investment advice.